logo-loader

Hemispherx Biopharma doses first patient with Ampligen in Phase 1 advanced breast cancer study

Published: 07:09 06 Apr 2019 AEDT

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Tom Equels tells Proactive Investors the company is excited to begin its Phase 1 studies using Ampligen as a combination therapy with Merck's Keytruda cancer drug at the Roswell Park Comprehensive Cancer Center in New York.

The study will establish the safety of the therapies to treat advanced breast cancer. Equels anticipates safety and efficacy indicators six to nine months after full enrollment of the study.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

6 hours, 39 minutes ago